Aristada Does Not Typically Increase Blood Pressure—It More Commonly Causes Orthostatic Hypotension
Aristada (aripiprazole lauroxil) is not associated with increasing blood pressure; rather, it may cause orthostatic hypotension due to α1-adrenergic receptor antagonism. According to the FDA label, aripiprazole may cause orthostatic hypotension with associated adverse reactions including dizziness, lightheadedness, and tachycardia, with risks greatest at treatment initiation and during dose escalation 1.
Key Clinical Points
Monitor for blood pressure decreases, not increases:
- In clinical trials, orthostatic hypotension (defined as ≥20 mmHg systolic BP drop with ≥25 bpm heart rate increase when moving from supine to standing) occurred in 0.5% of patients on Aristada 882 mg and 0.2% in long-term studies 1
- The mechanism is α1-adrenergic receptor antagonism, which can enhance the effects of antihypertensive medications 1
Patients at highest risk for hypotension include those with:
- Dehydration or hypovolemia
- Concurrent antihypertensive medication use
- History of cardiovascular disease (heart failure, MI, ischemia, conduction abnormalities)
- History of cerebrovascular disease
- Antipsychotic-naïve status 1
Rare Case Report Exception
One isolated case report described aripiprazole-associated hypertension with hyperaldosteronism in a 16-year-old male, where both hypertension and elevated aldosterone/PRA ratio resolved after discontinuing aripiprazole 2. However, this represents an extremely rare idiosyncratic reaction, not a typical drug effect.
Metabolic Profile
Aristada demonstrates a favorable metabolic profile overall:
- No clinically relevant changes in fasting glucose, lipids, or HbA1c over 12 weeks in controlled trials 3
- Modest weight gain (mean 0.74-0.86 kg vs 0.01 kg placebo over 12 weeks) 3
- Reductions in prolactin levels (unlike many other antipsychotics) 3
- Real-world data confirm better cardiometabolic outcomes compared to olanzapine, with similar total cholesterol but better body weight and blood pressure profiles 4
Clinical Management
When prescribing Aristada:
- Monitor orthostatic vital signs, especially in at-risk patients 1
- Consider lower starting doses in patients with cardiovascular risk factors 1
- If patient is on antihypertensive medications, monitor blood pressure and adjust antihypertensive doses accordingly 1
- Counsel patients about fall risk related to orthostatic hypotension, particularly early in treatment 1
The primary blood pressure concern with Aristada is hypotension, not hypertension. Routine monitoring should focus on detecting orthostatic changes rather than elevated readings.